Impact of Baseline Platelet Count on Complete Remission Rate, Risk of Bleeding Events, and Overall Prognosis in Patients with Newly Diagnosed Acute Myeloid Leukemia: A Single-Center Retrospective Cohort Study

We then examined three things — whether the patients achieved complete remission after initial chemotherapy, whether they suffered severe bleeding, and how long they survived. We found that the chance of achieving complete remission was similar in both groups. However, patients with low platelet counts at diagnosis were much more likely to experience severe bleeding, and their overall survival was significantly shorter.

For every 10×10⁹/L increase in baseline platelet count, the risk of severe bleeding dropped by about 21% and the risk of death within two years dropped by about 7%. These findings remained consistent even after we used statistical methods to balance the two groups. In summary, a simple baseline platelet count below 50×10⁹/L is a useful, inexpensive marker that helps doctors identify AML patients at higher risk of serious bleeding and poorer survival, so that closer monitoring and earlier supportive care can be given.